Braveheart Bio seeks $319M in IPO backed by a16z, signaling VC firm’s expanding appetite beyond crypto

Andreessen Horowitz, the venture capital firm that built its brand on crypto bets and Web3 conviction, is anchoring the IPO of a biotech company that has exactly zero blockchain references in its SEC filings. Braveheart Bio has filed to raise up to $318.8 million in an initial public offering on Nasdaq, and a16z Bio + Health is the lead backer. The company, which was founded just eight months ago in November 2025, is targeting a valuation of up to $1.2 billion. For a firm with no approved drugs and a lead candidate still in Phase 2 trials, that’s a bold ask. What Braveheart actually does Braveheart Bio is a clinical-stage biopharmaceutical company focused on hypertrophic cardiomyopathy, or HCM. In English: it’s developing an oral pill for a condition where the heart muscle gets abnormally thick, making it harder for the heart to pump blood. The company’s lead asset is BHB-1893, a cardiac myosin inhibitor in-licensed from Jiangsu Hengrui Pharmaceuticals, a major Chinese drugmaker. That licensing arrangement puts Braveheart in an increasingly crowded lane of US biotech firms sourcing promising compounds from China and running them through Western regulatory pathways. Positive Phase 2...